DHRNYSEhealth care

Danaher Corporation

$200.16Up+1.11 (+0.56%)

Research reviewed: Jul 12, 2026, 12:00 AM UTC

Research overview

Danaher Corporation operates in Life Sciences Tools and Services within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Open: 198.70
High: 200.84
Low: 198.00
Market Cap: 141.67B
P/E Ratio: 38.79
52 Week High: --
Dividend: 0.800%
Quarterly Dividend: --

3-month price context

The chart shows the recent 3-month trend so users can understand short-term market structure before opening the full research workspace.

Investment thesis

Base case: Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment. The base case remains conditional on biotech funding cycle staying manageable.
Bull case: Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment. A large installed base in life sciences and diagnostics supports repeat reagent, service and consumable demand. Disciplined integration of Masimo can broaden specialty diagnostics and create operating-improvement opportunities.
Bear case: Weak biotechnology funding or customer destocking could delay a sustained order recovery. Large acquisitions can bring debt, execution, regulatory and synergy-realization risk. Procurement policy, local competition and macro weakness can pressure diagnostics and life-science demand.

Key catalysts

Bioprocessing recovery
Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment.
Recurring consumables
A large installed base in life sciences and diagnostics supports repeat reagent, service and consumable demand.
Masimo integration
Disciplined integration of Masimo can broaden specialty diagnostics and create operating-improvement opportunities.

Principal risks

Biotech funding cycle
Weak biotechnology funding or customer destocking could delay a sustained order recovery.
Acquisition integration
Large acquisitions can bring debt, execution, regulatory and synergy-realization risk.
China exposure
Procurement policy, local competition and macro weakness can pressure diagnostics and life-science demand.

Latest earnings research

Q1 2026

Danaher's first-quarter 2026 results showed modest core growth, productivity-led adjusted earnings progress and strong cash generation, enabling an increased full-year earnings outlook as bioprocessing demand improved.

Valuation interpretation

A durable compounder interpretation depends on bioprocessing normalization and recurring consumables outgrowing instrument cyclicality.
Acquisition upside should be weighed against integration demands, financing costs and the quality of core organic growth.

Peer research

TMO ABBV JNJ

Continue in the research workspace

Keep DHR in context, run a multi-agent analysis, and monitor thesis changes.

Analyze DHR free

Explore the full research system

Each stage has a distinct job and leaves an auditable output for the next.

Research methodology Read market reports

Danaher Corporation

3-month price context

Key catalysts

Principal risks

Latest earnings research

Valuation interpretation

Peer research

Recent news

Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment

Jim Cramer on Danaher: “I Don’t Want You Anywhere Near That One”

Danaher (DHR) Wins CE Mark For Access P Tau217 Assay, Is The Stock A Bargain?

VTRS or DHR: Which Is the Better Value Stock Right Now?

1 Cash-Producing Stock with Competitive Advantages and 2 We Brush Off

Continue in the research workspace

Explore the full research system

Will Strength in Biotechnology Unit Continue to Drive DHR's Growth?

Data and research sources

Continue researching this stock